Filing Flows › Comparisons › RDGL vs PAVM
Vivos vs PAVmed: RDGL and PAVM compared
Vivos is the larger company: $36K of revenue in its latest quarter (Q2 2026) against $33K for PAVmed (Q2 2026). PAVmed is growing faster (+450% against +143% a year earlier).
Where the money goes: RDGL and PAVM
Vivos (RDGL) · Q2 2026
Vivos, Q2 2026: revenue $36K (+143% year over year), net loss $830K, operating cash flow −$740K. The chart follows the revenue to costs, profit and cash.
PAVmed (PAVM) · Q2 2026
PAVmed, Q2 2026: revenue $33K (+450% year over year), net loss $6.6M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
| Vivos (RDGL) | PAVmed (PAVM) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $36K | $33K |
| Revenue growth, Y/Y | +143% | +450% |
| Operating margin | n/m | n/m |
| Net earnings | −$830K | −$6.6M |
| Operating cash flow | −$740K | −$2.7M |
Questions
Which is bigger, Vivos or PAVmed?
Vivos is the larger company: $36K of revenue in its latest quarter (Q2 2026) against $33K for PAVmed (Q2 2026).
Is Vivos or PAVmed growing faster?
PAVmed is growing faster (+450% against +143% a year earlier).
More: Vivos earnings · how Vivos makes money · PAVmed earnings · how PAVmed makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.